Highlights a 2013 long portfolio of Apple, Micron, Marvell, and Cigna that would have beaten the market if left untouched.
Quality assessment: Reasonably structured retrospective based on public filings, but heavily hindsight-driven and limited to one manager; more observational than actionable DD.